Corrections to Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment [HEPATOLOGY 59 (2014) 974-985] doi: 10.1002/hep.26738;Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment

Hepatology

Volumn 59, Issue 3, 2014, Pages 974-985

  Chen, Chi Kuan ^a   Yang, Ching Yao ^a,b,c   Hua, Kuo Tai ^a,d   Ho, Ming Chih ^b   Johansson, Gunnar ^b   Jeng, Yung Ming ^b   Chen, Chiung Nien ^b,c   Chen, Min Wei ^a   Lee, Wei Jiunn ^e   Su, Jen Liang ^f,g   Lai, Tsung Ching ^d   Chou, Chi Chi ^h   Ho, Bing Ching ^a   Chang, Chuan Fa ⁱ   Lee, Po Huang ^b   Chang, King Jen ^b,c,j   Hsiao, Michael ^d   Lin, Ming Tsan ^b   Kuo, Min Liang ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d GENOMICS RESEARCH CENTER   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^g ASIA UNIVERSITY   (Taiwan)

^h INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

ⁱ NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^j CHENG CHING GENERAL HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTAXIN; LEUKOCYTE CELL DERIVED CHEMOTAXIN 2; PROTEIN TYROSINE PHOSPHATASE 1B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME LOCALIZATION; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKOCYTE; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR UPREGULATION; TANDEM MASS SPECTROMETRY; TUMOR VASCULARIZATION;

CARCINOMA, HEPATOCELLULAR; HEP G2 CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84896701555     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27143     Document Type: Erratum

References (28)

1. Huynh H, Ong RW, Li PY, Lee SS, Yang S, Chong LW, et al. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma. Anticancer Agents Med Chem 2011;11:560-575.
2. Hiraki Y, Inoue H, Kondo J, Kamizono A, Yoshitake Y, Shukunami C, Suzuki F. A novel growth-promoting factor derived from fetal bovine cartilage, chondromodulin II. Purification and amino acid sequence. J Biol Chem 1996;271:22657-22662.
3. Yamagoe S, Yamakawa Y, Matsuo Y, Minowada J, Mizuno S, Suzuki K. Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol Lett 1996;52:9-13.
4. Yamagoe S, Mizuno S, Suzuki K. Molecular cloning of human and bovine LECT2 having a neutrophil chemotactic activity and its specific expression in the liver. Biochim Biophys Acta 1998;1396:105-113.
5. Ovejero C, Cavard C, Perianin A, Hakvoort T, Vermeulen J, Godard C, et al. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. Hepatology 2004;40:167-176.
6. Anson M, Crain-Denoyelle AM, Baud V, Chereau F, Gougelet A, Terris B, et al. Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 2012;122:586-599.
7. Ong HT, Tan PK, Wang SM, Hian Low DT, Ooi LL, Hui KM. The tumor suppressor function of LECT2 in human hepatocellular carcinoma makes it a potential therapeutic target. Cancer Gene Ther 2011;18:399-406.
8. Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007;26:774-780.
9. Hua KT, Tan CT, Johansson G, Lee JM, Yang PW, Lu HY, et al. N-alpha-acetyltransferase 10 protein suppresses cancer cell metastasis by binding PIX proteins and inhibiting Cdc42/Rac1 activity. Cancer Cell 2011;19:218-231.
10. Brunelleschi S, Penengo L, Santoro MM, Gaudino G. Receptor tyrosine kinases as target for anti-cancer therapy. Curr Pharm Des 2002;8:1959-1972.
11. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-358.
12. Basilico C, Arnesano A, Galluzzo M, Comoglio PM, Michieli P. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem 2008;283:21267-21277.
13. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J 2004;23:2325-2335.
14. Bamford CV, Francescutti T, Cameron CE, Jenkinson HF, Dymock D. Characterization of a novel family of fibronectin-binding proteins with M23 peptidase domains from Treponema denticola. Mol Oral Microbiol 2010;25:369-383.
15. Sangwan V, Abella J, Lai A, Bertos N, Stuible M, Tremblay ML, Park M. Protein-tyrosine phosphatase 1B modulates early endosome fusion and trafficking of Met and epidermal growth factor receptors. J Biol Chem 2011;286:45000-45013.
16. Wang Z, Wang M, Carr BI. Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. J Cell Physiol 2010;224:559-565.
17. Sangwan V, Paliouras GN, Abella JV, Dube N, Monast A, Tremblay ML, Park M. Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. J Biol Chem 2008;283:34374-34383.
18. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-1595.
19. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009;49:491-503.
20. Herynk MH, Tsan R, Radinsky R, Gallick GE. Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis 2003;20:291-300.
21. Nakopoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J, Davaris PS. c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 2000;36:313-325.
22. Purcell R, Childs M, Maibach R, Miles C, Turner C, Zimmermann A, Sullivan M. HGF/c-Met related activation of beta-catenin in hepatoblastoma. J Exp Clin Cancer Res 2011;30:96.
23. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925.
24. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289-300.
25. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-6152.
26. Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A 2006;103:5090-5095.
27. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6:61-73.
28. Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003;94:321-327.